RGX-104 free acid is primarily investigated for its potential therapeutic applications in oncology. It functions as a small molecule activator of the liver X receptor (LXR), which plays a crucial role in regulating immune responses and cholesterol metabolism. By activating LXR, RGX-104 free acid promotes the expression of apolipoprotein E (ApoE), a protein involved in immune modulation and tumor suppression. This mechanism enhances the anti-tumor activity of immune cells, particularly in the tumor microenvironment, making it a promising candidate for cancer immunotherapy. It is being explored for its efficacy in treating various cancers, including those resistant to conventional therapies, by boosting the body's natural immune defenses against tumors.